Interferon-alpha does not cause significant cardiac dysfunction in patients with chronic active hepatitis

Area of Science:

• Hepatology
• Cardiology
• Pharmacology

Background:

• Recent clinical trials have raised concerns about cardiac adverse effects associated with interferon (INF) treatment.
• Recombinant INF-alpha is used to treat chronic active viral hepatitis (CAH).

Purpose of the Study:

• To prospectively evaluate the cardiac effects of recombinant INF-alpha treatment in patients with chronic active viral hepatitis (CAH).

Main Methods:

• Prospective study involving 31 CAH patients (16 type B, 14 type C, 1 type D) receiving recombinant INF-alpha-2a.
• Cardiac status monitored via medical history, physical exam, ECG, telecardiography, echocardiography, and heart rate variability at baseline, 6 months, and 6 months post-therapy.
• Patients with pre-existing cardiovascular conditions were included.

Main Results:

• No significant changes or adverse effects were detected in clinical examinations or cardiovascular tests throughout the study period.
• Pre-existing cardiovascular conditions (hypertension, myocardial infarction history, prosthetic valve, left hemiblock) did not worsen during or after INF therapy.
• Fever and tachycardia were noted during the initial weeks of therapy.

Conclusions:

• Cardiac adverse effects of interferon reported in previous studies appear questionable.
• Recombinant INF-alpha can be safely administered to CAH patients.
• Close monitoring for fever and tachycardia is recommended during the first two weeks of INF therapy, especially for high-risk cardiac patients.